Prognostic factors in multiple myeloma: It's in the genes

Clinical Cancer Research

Volumn 9, Issue 2, 2003, Pages 533-534

  Bergsagel, P Leif ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; BORTEZOMIB; GLUCOCORTICOID; PROTEASOME INHIBITOR; THALIDOMIDE;

CLINICAL TRIAL; DRUG ACTIVITY; EDITORIAL; GENE CLUSTER; GENE EXPRESSION; GENE TRANSLOCATION; GENETIC ANALYSIS; HUMAN; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROGNOSIS;

CHROMOSOME MAPPING; CHROMOSOMES, HUMAN, PAIR 14; CHROMOSOMES, HUMAN, PAIR 4; GENES, IMMUNOGLOBULIN; HUMANS; MULTIPLE MYELOMA; PROGNOSIS; TRANSLOCATION, GENETIC;

EID: 0037312473     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (13)

1. Bergsagel, P. L., Chesi, M. C., Nardini, E., Brents, L. A., Kirby, S. L., and Kuehl, W. M. Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma. Proc. Nat. Acad. Sci. USA, 93: 13931-13936, 1996.
2. Avet-Loiseau, H., Facon, T., Grosbois, B., Magrangeas, F., Rapp, M. J., Harousseau, J. L., Minvielle, S., and Bataille, R. Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. Blood, 99: 2185-2191, 2002.
3. Zhan, F., Hardin, J., Kordsmeier, B., Bumm, K., Zheng, M., Tian, E., Sanderson, R., Yang, Y., Wilson, C., Zangari, M., Anaissie, E., Morris, C., Muwalla, F., van Rhee, F., Fassas, A., Crowley, J., Tricot, G., Barlogie, B., and Shaughnessy, J., Jr. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood, 99: 1745-1757, 2002.
4. Yaccoby, S., Barlogie, B., and Epstein, J. Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations. Blood, 92: 2908-2913, 1998.
5. Hideshima, T., Chauhan, D., Podar, K., Schlossman, R. L., Richardson, P., and Anderson, K. C. Novel therapies targeting the myeloma cell and its bone marrow microenvironment. Semin. Oncol., 28: 607-612, 2001.
6. Berenson, J. R., Lichtenstein, A., Porter, L., Dimopoulos, M. A., Bordoni, R., George, S., Lipton, A., Keller, A., Ballester, O., Kovacs, M. J., Blacklock, H. A., Bell, R., Simeone, J., Reitsma, D. J., Heffernan, M., Seaman, J., and Knight, R. D. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N. Engl. J. Med., 334: 488-493, 1996.
7. Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., Zeddis, J., and Barlogie, B. Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med., 341: 1565-1571, 1999.
8. Hideshima, T., Richardson, P., Chauhan, D., Palombella, V. J., Elliott, P. J., Adams, J., and Anderson, K. C. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res., 61: 3071-3076, 2001.
9. Gregory, W. M., Richards, M. A., and Malpas, J. S. Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. J. Clin. Oncol., 10: 334-342, 1992.
10. Smadja, N. V., Bastard, C., Brigaudeau, C., Leroux, D., and Fruchart, C. Hypodiploidy is a major prognostic factor in multiple myeloma. Blood, 98: 2229-2238, 2001.
11. Facon, T., Avet-Loiseau, H., Guillerm, G., Moreau, P., Genevieve, F., Zandecki, M., Lai, J. L., Leleu, X., Jouet, J. P., Bauters, F., Harousseau, J. L., Bataille, R., and Mary, J. Y. Chromosome 13 abnormalities identified by FISH analysis and serum β2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood, 97: 1566-1571, 2001.
12. Chesi, M., Nardini, E., Brents, L. A., Schrock, E., Ried, T., Kuehl, W. M., and Bergsagel, P. L. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat. Genet., 16: 260-264, 1997.
13. Chiarle, R., Fan, Y., Piva, R., Boggino, H., Skolnik, J., Novero, D., Palestro, G., De Wolf-Peeters, C., Chilosi, M., Pagano, M., and Inghirami, G. S-phase kinase-associated protein 2 expression in non-Hodgkin's lymphoma inversely correlates with p27 expression and defines cells in S phase. Am. J. Pathol., 160: 1457-1466, 2002.